Syntekabio will present its AI-based drug discovery platforms DeepMatcher® and NEO-ARS™ at the UKC 2022 on August 19, aimed at fostering collaboration between U.S. and Korean professionals. The firm strives to revolutionize drug discovery methods and enhance cross-border business opportunities.
Syntekabio, a global leader in artificial intelligence-based drug discovery, will showcase its innovative platforms DeepMatcher® and NEO-ARS™ at the upcoming US-Korea Conference (UKC) in Arlington, Virginia, on August 19. These proprietary cloud platforms are designed to enhance the efficiency and effectiveness of drug discovery processes. The conference aims to foster collaboration between American and Korean professionals across various fields including science and entrepreneurship.
Syntekabio, headquartered in South Korea since 2009, specializes in AI-driven and big data methodologies for drug discovery and development. The UKC event promotes U.S.-Korea partnerships, featuring the 4th Innovation and Entrepreneurship Symposium, which creates avenues for companies with impactful technologies to network and collaborate. The firm is committed to producing transformative medicines that meet international standards.
In conclusion, Syntekabio’s presentation at the UKC 2022 highlights its commitment to innovation in drug discovery through AI technology. With its platforms poised for launch, the company positions itself as a prominent player in the biotechnology sector, leveraging international partnerships to enhance healthcare solutions. Interested parties can visit their website for more detailed information.
Original Source: www.globenewswire.com
